Literature DB >> 31571918

MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells.

Xiaorui Wang1,2,3,4,5,6, Zhongsheng Tong1,2,3,4,5, Hong Liu2,3,4,5,6,7.   

Abstract

PURPOSE: This research was to investigate the role of miR-223-3p targeting epithelial cell transforming sequence 2 oncogene (ECT2) in activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer (BC) cells.
METHODS: The human BC cell lines MDA-MB-468 were used for the experiment. They were divided into six groups: blank group (no plasmid transfection), NC group (negative control, transfected empty plasmid), miR-223-3p mimic group (transfected miR-223-3p mimic plasmid), miR-223-3p inhibitor group (transfected miR-223-3p inhibitor plasmid), si-ECT2 group (transfected si ECT2 plasmid) and miR-223-3p mimic+oe-ECT2 group (transfected with miR-223-3p mimic plasmid and ECT2 plasmid).
RESULTS: Compared with the NC group, the mRNA and protein expression of Bax in miR-223-3p mimic and si-ECT2 groups were significantly increased, while the mRNA and protein expression of ECT2, Bcl-2, vascular endothelial growth factor (VEGF), and TGF-β1 were significantly decreased (all P<0.05). Compared with the NC group, the expression of miR-223-3p and the mRNA and protein expression of Bax were significantly decreased in the miR-223-3p inhibitor group, while the mRNA and protein expression of ECT2, Bcl-2, VEGF and TGF-β1 were significantly increased (both P<0.05). Compared with the single processing group, the mRNA and protein expression of Bax in the miR-223-3p mimic+si-ECT2 group were significantly increased, while the mRNA and protein expression of ECT2, Bcl-2, VEGF, and TGF-β1 were significantly decreased (all P<0.05).
CONCLUSION: MiR-223-3p targets and inhibits the expression of ECT2, thus inhibiting the invasion and migration of BC cells, and promoting cell apoptosis. miR-223-3p plays a protective role in BC.
© 2019 Wang et al.

Entities:  

Keywords:  ECT2; breast cancer; invasion; miR-223-3p; migration

Year:  2019        PMID: 31571918      PMCID: PMC6756370          DOI: 10.2147/OTT.S217019

Source DB:  PubMed          Journal:  Onco Targets Ther        ISSN: 1178-6930            Impact factor:   4.147


  30 in total

1.  Clinical features and prognosis of breast cancer with gastric metastasis.

Authors:  Joohyun Hong; Youjin Kim; Jangho Cho; Sung Won Lim; Song Ee Park; Hee Kyung Kim; Hansang Lee; Soo Youn Cho; Ji-Yeon Kim; Jin Seok Ahn; Young-Hyuck Im; Yeon Hee Park
Journal:  Oncol Lett       Date:  2018-11-23       Impact factor: 2.967

Review 2.  Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.

Authors:  Thomas Simon; Teresa Gagliano; Georgios Giamas
Journal:  Trends Mol Med       Date:  2017-02-02       Impact factor: 11.951

3.  TGF-β upregulates miR-181a expression to promote breast cancer metastasis.

Authors:  Molly A Taylor; Khalid Sossey-Alaoui; Cheryl L Thompson; David Danielpour; William P Schiemann
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

4.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Authors:  Harold J Burstein; Anthony D Elias; Hope S Rugo; Melody A Cobleigh; Antonio C Wolff; Peter D Eisenberg; Mary Lehman; Bonne J Adams; Carlo L Bello; Samuel E DePrimo; Charles M Baum; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-03-17       Impact factor: 44.544

5.  Expression and prognostic significance of ECT2 in invasive breast cancer.

Authors:  Hong-Kun Wang; Jian-Fang Liang; Hui-Xia Zheng; Hong Xiao
Journal:  J Clin Pathol       Date:  2017-10-19       Impact factor: 3.411

6.  MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5.

Authors:  Wang Renjie; Liang Haiqian
Journal:  Cancer Lett       Date:  2014-10-08       Impact factor: 8.679

7.  TGF-β1 induces HMGA1 expression in human breast cancer cells: implications of the involvement of HMGA1 in TGF-β signaling.

Authors:  Xuyu Zu; Jing Zhong; Jingjing Tan; Li Tan; Dong Yang; Qinghai Zhang; Wenjun Ding; Wen Liu; Gebo Wen; Jianghua Liu; Renxian Cao; Yuyang Jiang
Journal:  Int J Mol Med       Date:  2015-01-05       Impact factor: 4.101

8.  miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.

Authors:  Jing Han; Fengyi Zhao; Jing Zhang; Haizhen Zhu; Hu Ma; Xuetao Li; Lina Peng; Jianguo Sun; Zhengtang Chen
Journal:  Int J Oncol       Date:  2016-02-19       Impact factor: 5.650

9.  Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer.

Authors:  Hanna Aula; Tanja Skyttä; Suvi Tuohinen; Tiina Luukkaala; Mari Hämäläinen; Vesa Virtanen; Pekka Raatikainen; Eeva Moilanen; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Radiat Oncol       Date:  2018-10-19       Impact factor: 3.481

10.  Large-scale synthesis of monodisperse Prussian blue nanoparticles for cancer theranostics via an "in situ modification" strategy.

Authors:  Yanjun Xu; Yang Zhang; Xiaojun Cai; Wei Gao; Xiuzhen Tang; Yini Chen; Jie Chen; Li Chen; Qiwei Tian; Shiping Yang; Yuanyi Zheng; Bing Hu
Journal:  Int J Nanomedicine       Date:  2018-12-27
View more
  16 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  ECT2 promotes malignant phenotypes through the activation of the AKT/mTOR pathway and cisplatin resistance in cervical cancer.

Authors:  Xiaoli Liu; Junhua Zhang; Shuang Ju; Lu Liu; Yu Sun; Lingyu Guo; Qianwei Zhen; Sai Han; Wei Lu; Youzhong Zhang
Journal:  Cancer Gene Ther       Date:  2022-09-02       Impact factor: 5.854

3.  Upregulation of CCT-3 Induces Breast Cancer Cell Proliferation Through miR-223 Competition and Wnt/β-Catenin Signaling Pathway Activation.

Authors:  Hongbo Qu; Fang Zhu; Huaying Dong; Xiongqiang Hu; Mingli Han
Journal:  Front Oncol       Date:  2020-09-24       Impact factor: 6.244

4.  miR-30a-5p Regulates Viability, Migration, and Invasion of Lung Adenocarcinoma Cells via Targeting ECT2.

Authors:  Sangsang Chen; Xuqing Zhu; Jing Zheng; Tingting Xu; Yinmin Xu; Feng Chen
Journal:  Comput Math Methods Med       Date:  2021-07-07       Impact factor: 2.238

5.  Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4.

Authors:  Yan Liu; Hejia Zhang; Hui Wang; Jiarui Du; Peng Dong; Meihan Liu; Yuanqiang Lin
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 6.  Circulating exosomal miRNAs and cancer early diagnosis.

Authors:  L Zhu; L Zhao; Q Wang; S Zhong; X Guo; Y Zhu; J Bao; K Xu; S Liu
Journal:  Clin Transl Oncol       Date:  2021-09-15       Impact factor: 3.405

Review 7.  MicroRNA Regulation of the Small Rho GTPase Regulators-Complexities and Opportunities in Targeting Cancer Metastasis.

Authors:  Brock A Humphries; Zhishan Wang; Chengfeng Yang
Journal:  Cancers (Basel)       Date:  2020-04-28       Impact factor: 6.639

8.  MicroRNA related prognosis biomarkers from high throughput sequencing data of kidney renal clear cell carcinoma.

Authors:  Minjiang Huang; Ti Zhang; Zhi-Yong Yao; Chaoqung Xing; Qingyi Wu; Yuan-Wu Liu; Xiao-Liang Xing
Journal:  BMC Med Genomics       Date:  2021-03-09       Impact factor: 3.063

9.  Exosomes from LPS-Stimulated hDPSCs Activated the Angiogenic Potential of HUVECs In Vitro.

Authors:  Xiangyu Huang; Wei Qiu; Yuhua Pan; Jianjia Li; Zhao Chen; Kaiying Zhang; Yifei Luo; Buling Wu; Wenan Xu
Journal:  Stem Cells Int       Date:  2021-04-15       Impact factor: 5.443

10.  MiR-223-3p inhibits rTp17-induced inflammasome activation and pyroptosis by targeting NLRP3.

Authors:  Fu-Quan Long; Cai-Xia Kou; Ke Li; Juan Wu; Qian-Qiu Wang
Journal:  J Cell Mol Med       Date:  2020-11-03       Impact factor: 5.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.